These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 25324141)

  • 1. New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.
    Gojo I; Karp JE
    Clin Cancer Res; 2014 Dec; 20(24):6233-41. PubMed ID: 25324141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia.
    Wang A; Zhong H
    Hematology; 2018 Dec; 23(10):729-739. PubMed ID: 29902132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukemic stem cell signatures in Acute myeloid leukemia- targeting the Guardians with novel approaches.
    Thakral D; Gupta R; Khan A
    Stem Cell Rev Rep; 2022 Jun; 18(5):1756-1773. PubMed ID: 35412219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues.
    Valent P; Bauer K; Sadovnik I; Smiljkovic D; Ivanov D; Herrmann H; Filik Y; Eisenwort G; Sperr WR; Rabitsch W
    Stem Cells Transl Med; 2020 Nov; 9(11):1331-1343. PubMed ID: 32657052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concise review: Leukemia stem cells in personalized medicine.
    Guzman ML; Allan JN
    Stem Cells; 2014 Apr; 32(4):844-51. PubMed ID: 24214290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between leukaemic stem cells and hematopoietic stem cells and their clinical application.
    Wang SSY
    Leuk Lymphoma; 2022 Jul; 63(7):1524-1533. PubMed ID: 35067128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploiting epigenetically mediated changes: Acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment.
    Kogan AA; Lapidus RG; Baer MR; Rassool FV
    Adv Cancer Res; 2019; 141():213-253. PubMed ID: 30691684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development.
    Yao Y; Li F; Huang J; Jin J; Wang H
    Exp Hematol Oncol; 2021 Jul; 10(1):39. PubMed ID: 34246314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia.
    Kirtonia A; Pandya G; Sethi G; Pandey AK; Das BC; Garg M
    J Mol Med (Berl); 2020 Aug; 98(8):1069-1091. PubMed ID: 32620999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells.
    Pandolfi A; Barreyro L; Steidl U
    Stem Cells Transl Med; 2013 Feb; 2(2):143-50. PubMed ID: 23349328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies.
    Bruserud Ø; Aasebø E; Hernandez-Valladares M; Tsykunova G; Reikvam H
    Expert Opin Drug Discov; 2017 Oct; 12(10):1053-1065. PubMed ID: 28748730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Microenvironment in Resistance to Therapy in AML.
    Tabe Y; Konopleva M
    Curr Hematol Malig Rep; 2015 Jun; 10(2):96-103. PubMed ID: 25921386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the bone marrow microenvironment in acute leukemia.
    Karantanou C; Godavarthy PS; Krause DS
    Leuk Lymphoma; 2018 Nov; 59(11):2535-2545. PubMed ID: 29431560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic targeting and personalized approaches for AML.
    Roboz GJ
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):44-51. PubMed ID: 25696833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Bone Marrow Microenvironment on Leukemic Stem Cells: Breaking Up an Intimate Relationship.
    Agarwal P; Bhatia R
    Adv Cancer Res; 2015; 127():227-52. PubMed ID: 26093902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy.
    Sami SA; Darwish NHE; Barile ANM; Mousa SA
    Curr Treat Options Oncol; 2020 Jan; 21(1):3. PubMed ID: 31933183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in AML: prognostic and therapeutic implications.
    DiNardo CD; Cortes JE
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):348-355. PubMed ID: 27913501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?
    Megías-Vericat JE; Martínez-Cuadrón D; Solana-Altabella A; Montesinos P
    Expert Rev Hematol; 2020 Oct; 13(10):1057-1065. PubMed ID: 32869672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A potential area of use for immune checkpoint inhibitors: Targeting bone marrow microenvironment in acute myeloid leukemia.
    Aru B; Pehlivanoğlu C; Dal Z; Dereli-Çalışkan NN; Gürlü E; Yanıkkaya-Demirel G
    Front Immunol; 2023; 14():1108200. PubMed ID: 36742324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Personalized Molecular Therapy for Acute Myeloid Leukemia.
    Engen CB; Hajjar E; Gjertsen BT
    Curr Pharm Biotechnol; 2016; 17(1):20-9. PubMed ID: 26420051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.